Braxia Scientific Corp.

As of December 31, 2023, Braxia Scientific Corp. has 263.71M shares outstanding.

These figures are as of December 31, 2023. The price-to-sales ratio is 0.57, and the price-to-book ratio stands at -3.60.

These figures are as of December 31, 2023. The EV/Sales ratio of 0.83 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of December 31, 2023, Braxia Scientific Corp. maintains a current ratio of 0.18, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -174.02, indicating conservative leverage, while an interest coverage ratio of -65.07 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2023, Braxia Scientific Corp. posted a negative return on equity (ROE) of -735.47, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -164.33, reflecting losses generated across the asset base. Inventory turnover of 401.89 indicates how many times Braxia Scientific Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on June 21, 2024, Braxia Scientific Corp.'s stock has declined approximately 75.00% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

Over the twelve months ended December 31, 2023, Braxia Scientific Corp. posted a gross margin of 14.67, reflecting its pricing power and cost economics. The operating margin of -189.91 and net profit margin of -436.37 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2023. Free cash flow yield is negative at -202.47: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -90.30, meaning Braxia Scientific Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2023, Braxia Scientific Corp. has an Altman Z-Score of -121.46, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.